A Prospective, Randomized, Double-blind Phase 2b Clinical Trial to Investigate the Efficacy and Safety of SP-8203 in Patients With Acute Ischemic Stroke Requiring Recombinant Tissue Plasminogen Activator (rtPA) Standard of Care
Latest Information Update: 10 Mar 2023
At a glance
- Drugs Otaplimastat (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SP-8203-2002
- Sponsors Shin Poong Pharmaceutical
- 20 Dec 2020 Status changed from active, no longer recruiting to completed.
- 09 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 22 Sep 2020 Planned End Date changed from 31 Oct 2020 to 20 Dec 2020.